We are monitoring the impact of COVID-19 on APAC RNAi Drug Delivery Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1891
Share on
Share on

Asia-Pacific RNAi Drug Delivery Market Research Report – Segmented By Drug Delivery, Therapeutic Application & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1891
Pages: 138

APAC RNAi Drug Delivery Market Size (2021 to 2026)

The size of the Asia-Pacific RNAi Drug Delivery Market has been estimated at USD 9.66 billion in 2021. It is projected to reach USD 34.52 billion by 2026, at a CAGR of 29% during the forecast period.

The APAC market for RNAi drug delivery is expected to be driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and other genetic disorders. In addition, a rising number of academic research and activities are stimulating the use of novel drug delivery methods and drug enhancements by boosting stability. Furthermore, other factors such as increasing awareness about the RNAi therapies and their benefits, growing disposable income, and favorable reimbursement policies are propelling the market growth. 

Due to the numerous benefits offered by RNA interference technology in medicine and therapeutics, the therapeutics segment is expected to accelerate. Moreover, the government authorities in developing countries are taking steps to provide improved medication delivery to all segments of the population to improve health care services, fueling the RNAi drug delivery market's growth. 

On the other hand, the growing geriatric population, the prevalence of infectious diseases, and a significant increase in the demand for RNAi drug delivery technologies in emerging countries such as China, India, and Japan are expanding the APAC Regional market growth. Furthermore, the medical research companies are constantly working to produce RNA treatments, and key market players are adopting key market strategies to gain a competitive advantage. The strategies include Partnerships, mergers, and acquisitions. 

However, the high cost of RNAi therapy development is expected to be impeding the market growth. In addition, other factors such as an increased risk of failure, lack of skilled specialists in drug control laboratories, and a lack of proper distribution networks of RNAi medication delivery due to the weak healthcare infrastructure in developing countries are constraining the market development.

This research report on the Asia-Pacific RNAi Drug Delivery market has been segmented and sub-segmented into the following categories.

By Drug Delivery:

  • Nanoparticle Drug Delivery Technology
  • Nucleic Acid Drug Delivery Technology
  • Aptamer Drug Delivery Technology
  • Pulmonary Drug Delivery Technology

By Therapeutic Application:

  • Infectious Diseases
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Metabolic Disorders

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The APAC is one of the fasting growing regions globally in the RNAi drug delivery market. The regional market growth is attributed to the growing healthcare infrastructure, significant investments, and favorable reimbursement policies. The Asia Pacific region accounted for the most significant proportion of the worldwide RNAi medication market in 2020. Emerging countries such as China, India, and Japan significantly contribute to the APAC regional market growth. RNAi technology allows for a focused approach to cancer treatment, which is ideal for receiving precise treatment. The rise in chronic diseases such as cancer and carter dysfunction has resulted in a steady increase in demand for RNAi drugs across the region. Scientists are currently working to identify the genes that cause cancer and develop an RNAi drug to combat them. For a few years, this approach has been quickly growing.

China accounted for the largest share of the RNAi market over the forecast period and is most likely to witness a predominant share in the coming years. The presence of well-established healthcare infrastructure, technological advancements, and prevalence of chronic diseases contribute to the country's market growth.

KEY MARKET PLAYERS:

Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc. are some of the key companies in the APAC RNAi drug delivery market.

1.Introduction                                                  

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                       

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 Epidemology                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                    

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

5. Market Segmentation                                                              

                5.1 Drug delivery                                             

                                5.1.1 Introduction                           

                                5.1.2 nanoparticle drug delivery technology                        

                                5.1.3 pulmonary drug delivery technology                           

                                5.1.4 nucleic acid drug delivery technology                          

                                5.1.5  aptamer drug delivery technology                               

                                5.1.6  Y-o-Y Growth Analysis, By Drug Delivery                   

                                5.1.7  Market Attractiveness Analysis, By Drug delivery                 

                                5.1.8 Market Share Analysis, By drug Delivery                    

                5.2 Therapeutic Application                                        

                                5.2.1 Introduction                           

                                5.2.2 infectious diseases                              

                                5.2.3 cardiology                

                                5.2.4 oncology                  

                                5.2.5 neurology                

                                5.2.6 ophthalmology                      

                                5.2.7 metabolic disorders                            

                                5.2.8  Y-o-Y Growth Analysis, By Therapeutic Application                              

                                5.2.9  Market Attractiveness Analysis, By Therapeutic Application                            

                                5.2.10 Market Share Analysis, By Therapeutic Application                             

6. Geographical Analysis                                                              

                6.1 Introduction                                               

                                6.1.1 Regional Trends                    

                                6.1.2 Impact Analysis                     

                                6.1.3 Y-o-Y Growth Analysis                        

                                                6.1.3.1 By Geographical Area     

                                                6.1.3.2 By Drug Delivery               

                                                6.1.3.3 By Therapeutic Application           

                                6.1.4  Market Attractiveness Analysis                     

                                                6.1.4.1 By Geographical Area     

                                                6.1.4.2 By Drug Delivery               

                                                6.1.4.3 By Therapeutic Application           

                                6.1.5  Market Share Analysis                      

                                                6.1.5.1 By Geographical Area     

                                                6.1.5.2 By Drug Delivery               

                                                6.1.5.3 By Therapeutic Application           

                6.2 China                                             

                6.3 India                                              

                6.4 Japan                                            

                6.5 South Korea                                               

                6.6 Australia                                      

7.Strategic Analysis                                                        

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

8.Market Leaders' Analysis                                                         

                8.1 Alnylam Pharmaceuticals Inc.                                             

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Financial analysis                  

                                8.1.4 Recent Developments                       

                                8.1.5 SWOT analysis                       

                                8.1.6 Analyst View                          

                8.2 Merck & Co. Inc                                        

                8.3 Access Pharmaceuticals Inc.                                

                8.4 Dicerna Pharmaceuticals Inc.                                              

                8.5 Tekmira Pharmaceuticals Corp.                                          

                8.6 Isis Pharmaceuticals Inc                                         

                8.7 Calondo Pharmaceuticals Inc.                                             

                8.8 Marina Biotech Inc.                                 

                8.9 RXi Pharmaceuticals Corp                                     

                8.10 Quark Pharmaceuticals Inc                                

                8.11 Silence Therapeutics plc                                     

                8.12 Traversa Therapeutics Inc.                                 

                8.13 Tacere Therapeutics Inc                                      

                8.14 Sirnaomics Inc.                                        

                8.15 PhaseRx Inc.                                            

9.Competitive Landscape                                                            

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

10.Market Outlook and Investment Opportunities                                                          

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific RNAi Drug Delivery Market, By Drug Delivery, From 2021 to 2026 (USD billion)
  2. Asia-Pacific nanoparticle drug delivery technology Market, By Region, From 2021 to 2026 (USD billion)
  3. Asia-Pacific pulmonary drug delivery technology Market, By Region, From 2021 to 2026 (USD billion)
  4. Asia-Pacific nucleic acid drug delivery technology  Market, By Region, From 2021 to 2026 (USD billion)
  5. Asia-Pacific aptamer drug delivery technology Market, By Region, From 2021 to 2026 (USD billion)
  6. Asia-Pacific RNAi Drug Delivery Market, By Therapeutic Applications, From 2021 to 2026 (USD billion)
  7. Asia-Pacific infectious diseases Market, By Region, From 2021 to 2026 (USD billion)
  8. Asia-Pacific cardiology Market, By Region, From 2021 to 2026 (USD billion)
  9. Asia-Pacific oncology Market, By Region, From 2021 to 2026 (USD billion)
  10. Asia-Pacific neurology Market, By Region, From 2021 to 2026 (USD billion)
  11. Asia-Pacific ophthalmology Market, By Region, From 2021 to 2026 (USD billion)
  12. Asia-Pacific metabolic disorders Market, By Region, From 2021 to 2026 (USD billion)
  13. Japan RNAi Drug Delivery Market, By Drug Delivery, From 2021 to 2026 (USD billion)
  14. Japan RNAi Drug Delivery Market, By Therapeutic Applications, From 2021 to 2026 (USD billion)
  15. China RNAi Drug Delivery Market, By Drug Delivery, From 2021 to 2026 (USD billion)
  16. China RNAi Drug Delivery Market, By Therapeutic Applications, From 2021 to 2026 (USD billion)
  17. India RNAi Drug Delivery Market, By Drug Delivery, From 2021 to 2026 (USD billion)
  18. India RNAi Drug Delivery Market, By Therapeutic Applications, From 2021 to 2026 (USD billion)
  19. Australia RNAi Drug Delivery Market, By Drug Delivery, From 2021 to 2026 (USD billion)
  20. Australia RNAi Drug Delivery Market, By Therapeutic Applications, From 2021 to 2026 (USD billion)
  21. South Korea RNAi Drug Delivery Market, By Drug Delivery, From 2021 to 2026 (USD billion)
  22. South Korea RNAi Drug Delivery Market, By Therapeutic Applications, From 2021 to 2026 (USD billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample